Summarized by Masters of Longevity from PR Newswire.
A news release about a translational cell therapy partner joining a state regenerative medicine agency’s industry resource program, outlining how the partnership will support translational and GMP-readiness for researchers.
Key Takeaways
- The designation, formalized through a Memorandum of Understanding between the two organizations, makes NueCell Bio a resource for CIRM-funded researchers and companies advancing programs from discovery toward translational and clinical-stage development.
- California voters created CIRM to accelerate stem cell and gene therapies for people with unmet medical need.
- Since 2004, Californians have entrusted CIRM with $8.5 billion to support promising discoveries through clinical trials, as well as train a regenerative medicine workforce, strengthen the state's biotechnology economy, and expand access to transformative treatment.
